Catalog No.: PC-43493Not For Human Use, Lab Use Only.
Pidnarulex (CX-5461) is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I, selectively inhibits rRNA synthesis in HCT-116 cells with IC50 of 142 nM, 200-fold selectivity over Pol II.
Pidnarulex (CX-5461) is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I, selectively inhibits rRNA synthesis in HCT-116 cells with IC50 of 142 nM, 200-fold selectivity over Pol II.
Pidnarulex (CX-5461) inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines.
Pidnarulex (CX-5461) demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models.
